Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in Citi's 2025 Biopharma Back to School Summit.
The presentation is scheduled for Wednesday, September 3, at 7:30 AM PT/10:30 AM ET. Investors can access the webcast through Allogene's website, with replays available for approximately 30 days after the event.
Allogene Therapeutics (Nasdaq: ALLO), azienda biotecnologica in fase clinica che sviluppa terapie CAR T allogeniche (AlloCAR T™) per tumori e malattie autoimmuni, ha annunciato la sua partecipazione al Citi's 2025 Biopharma Back to School Summit.
La presentazione è prevista per mercoledì 3 settembre, alle 7:30 PT / 10:30 ET. Gli investitori potranno seguire il webcast tramite il sito web di Allogene; le registrazioni saranno disponibili in replay per circa 30 giorni dopo l’evento.
Allogene Therapeutics (Nasdaq: ALLO), una compañía biotecnológica en fase clínica centrada en desarrollar terapias CAR T alogénicas (AlloCAR T™) para el cáncer y enfermedades autoinmunes, ha anunciado su participación en el Citi's 2025 Biopharma Back to School Summit.
La presentación tendrá lugar el miércoles 3 de septiembre a las 7:30 AM PT / 10:30 AM ET. Los inversores podrán acceder a la transmisión en directo desde la web de Allogene; las repeticiones estarán disponibles durante aproximadamente 30 días tras el evento.
Allogene Therapeutics (Nasdaq: ALLO)는 암 및 자가면역질환을 위한 동종(알로) CAR T( AlloCAR T™) 치료제를 개발하는 임상 단계의 바이오텍 회사로, Citi's 2025 Biopharma Back to School Summit에 참여한다고 발표했습니다.
발표는 9월 3일 수요일, 오전 7:30 PT / 오전 10:30 ET에 예정되어 있습니다. 투자자들은 Allogene 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 이벤트 종료 후 약 30일간 다시보기(replay)가 제공됩니다.
Allogene Therapeutics (Nasdaq: ALLO), société de biotechnologie en phase clinique spécialisée dans le développement de thérapies CAR T allogéniques (AlloCAR T™) contre le cancer et les maladies auto-immunes, a annoncé sa participation au Citi's 2025 Biopharma Back to School Summit.
La présentation est prévue le mercredi 3 septembre à 7h30 PT / 10h30 ET. Les investisseurs pourront suivre le webdiffusion via le site d'Allogene ; les rediffusions seront disponibles pendant environ 30 jours après l'événement.
Allogene Therapeutics (Nasdaq: ALLO), ein Biotech-Unternehmen in klinischer Phase, das allogene CAR‑T‑Therapien (AlloCAR T™) für Krebs und Autoimmunerkrankungen entwickelt, hat seine Teilnahme am Citi's 2025 Biopharma Back to School Summit angekündigt.
Die Präsentation ist geplant für Mittwoch, den 3. September, um 7:30 Uhr PT / 10:30 Uhr ET. Anleger können das Webcast über die Website von Allogene verfolgen; Aufzeichnungen stehen etwa 30 Tage nach der Veranstaltung als Replay zur Verfügung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September.
Citi's 2025 Biopharma Back to School Summit
Wednesday, September 3
7:30AM PT/10:30AM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
When is Allogene Therapeutics (ALLO) presenting at Citi's 2025 Biopharma Summit?
How can investors access Allogene's (ALLO) Citi Summit presentation?
How long will Allogene's (ALLO) Citi Summit presentation replay be available?
What is Allogene Therapeutics' (ALLO) main focus area?
